Ana Fernández Montés

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

Manuel Cobo, Dolores Isla, Bartomeu Massutí et al. · Journal of Clinical Oncology · 2007 · 442 citations · Full text

Copy number signatures and mutational processes in ovarian carcinoma

Geoff Macintyre, Teodora Goranova, Dilrini De Silva et al. · Nature Genetics · 2018 · 433 citations · Full text

Somatic Variant, Tumor Heterogeneity, Pathology +2

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors

Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris et al. · Clinical Cancer Research · 2017 · 236 citations

A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)

Luis Paz‐Ares, J. M. Sanchez, A. García et al. · Journal of Clinical Oncology · 2006 · 162 citations

Advanced Nsclc, Medicine, Tyrosine Kinase +14

Snai1 and Snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines

David Olmeda, Ana Fernández Montés, Gema Moreno‐Bueno et al. · Oncogene · 2008 · 111 citations

Oncogenic Agent, Medicine, Tumor Growth +9